Trial · NCT04847921
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | percentage of patients with improvement of the principal infectious diagnosis by clinical assessment within 7 days | 7 days from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by universally accepted clinically observed clinical features (i.e. deffervescence; improved pain, swelling, purulence) |
| Primary | percentage of patients with improvement of the principal infectious diagnosis by clinical assessment within 4 weeks | 4 weeks from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by universally accepted clinically observed clinical features (i.e. deffervescence; improved pain, swelling, purulence) |
| Primary | percentage of patients with improvement of the principal infectious diagnosis by clinical assessment within 6 weeks | 6 weeks from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by universally accepted clinically observed clinical features (i.e. deffervescence; improved pain, swelling, purulence) |
| Primary | percentage of patients with improvement of the principal infectious diagnosis by improvement in imaging within 6 weeks (where applicable) | 6 weeks from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by improved lesions on imaging |
| Primary | percentage of patients with improvement in Erythrocyte Sedimentation Rate (ESR) (where applicable) within 7 days | 7 days from the start of dalbavancin therapy | improvement in ESR (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in Erythrocyte Sedimentation Rate (ESR) (where applicable) within 4 weeks | 4 weeks from the start of dalbavancin therapy | improvement in ESR (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in Erythrocyte Sedimentation Rate (ESR) (where applicable) within 6 weeks | 6 weeks from the start of dalbavancin therapy | improvement in ESR (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in C-Reactive Protein (CRP) (where applicable) within 7 days | 7 days from the start of dalbavancin therapy | improvement in CRP (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in C-Reactive Protein (CRP) (where applicable) within 4 weeks | 4 weeks from the start of dalbavancin therapy | improvement in CRP (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in C-Reactive Protein (CRP) (where applicable) within 6 weeks | 6 weeks from the start of dalbavancin therapy | improvement in CRP (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement of the principal infectious diagnosis by resolution of bacteremia (where applicable) within 7 days | 7 days from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by resolution of bacteremia (where applicable) |
| Primary | percentage of patients with relapse of the principal infectious diagnosis | 12 months from the start of antimicrobial therapy or from the achievement of source control (whichever comes later) | evidence of relapse (excluding re-infection) assessed at each follow up visit until the end of study follow up (censored once occurred). |
| Primary | percentage of patients with at least one adverse event | 12 months | Safety and tolerability of dalbavancin evaluation as measured by the number of any confirmed or suspected treatment-emergent (not necessarily treatment related) complications or adverse events assessed daily during hospitalization and at each study visit after discharge from inpatient treatment (immediately after 2nd dose of dalbavancin, unless prevented by acute development of a medical condition requiring further hospitalization) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04847921/registered